St Luke's Infectious Disease Associates, Duluth, Minnesota, USA.
Clin Gastroenterol Hepatol. 2011 Dec;9(12):1044-9. doi: 10.1016/j.cgh.2011.08.014. Epub 2011 Aug 24.
Clostridium difficile infection is increasing in incidence, severity, and mortality. Treatment options are limited and appear to be losing efficacy. Recurrent disease is especially challenging; extended treatment with oral vancomycin is becoming increasingly common but is expensive. Fecal microbiota transplantation is safe, inexpensive, and effective; according to case and small series reports, about 90% of patients are cured. We discuss the rationale, methods, and use of fecal microbiota transplantation.
艰难梭菌感染的发病率、严重程度和死亡率都在上升。治疗选择有限，而且疗效似乎正在下降。复发性疾病尤其具有挑战性；口服万古霉素的延长治疗越来越常见，但费用昂贵。粪便微生物群移植是安全、廉价和有效的；根据病例和小系列报告，约 90%的患者被治愈。我们讨论了粪便微生物群移植的原理、方法和用途。
